In this episode of Investing in Cannabis, Brandon David interviews David Lampach, the co-founder and CEO of Steep Hill, at the company’s headquarters in California. Steep Hill is one of the country’s leading cannabis science and technology firms. Steep Hill’s core business is testing and analyzing medical and recreational marijuana to ensure compliance with public safety standards. In addition to its core business, Steep Hill is also an innovative R&D Lab that has developed and commercialized two highly-differentiated and proprietary products: the QuantaCann™ and the GenKit™.

Since opening its first commercial cannabis lab in 2008, Steep Hill has grown immensely and now has labs in California, Colorado, Nevada, New Mexico and Washington and will expand to Oregon later this year. Lampach discusses the need to test, the shift to CO2 extraction and its pros and cons, the economics of the cannabis market, the early days of Steep Hill, the technology the company uses, differences in state regulations, partnerships with academic programs, his recent visit to Israel, the trade-off between innovation and regulation, the company’s capital-raising progress, Steep Hill’s intellectual property development, challenges with the publicly-traded cannabis stocks and the entrance of institutional funds in the cannabis industry

Watch Brandon David’s interview:  https://youtu.be/KebbTA-knjU

Published by NCV Newswire

The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.